In 574 patients with platinum-ineligible recurrent ovarian cancer on bevacizumab plus chemotherapy, adding atezolizumab did not significantly improve OS (HR 0.83; P=0.06; median 14.2 vs 13.0 months) or PFS (HR 0.87; P=0.12) vs placebo.
RCTn = 574
Harter et al. Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial